Adoptive immunotherapy with enhanced T lymphocyte survival

Details Adoptive immunotherapy with enhanced T lymphocyte survival Adoptive immunotherapy with enhanced T lymphocyte survival

2011-08-16

2011-08-16

Wehbe, Anne Marie S (Department: 1633)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S372300, C424S093210

Reexamination Certificate

active

07998736

ABSTRACT:
The invention provides for compositions, e.g., pharmaceutical compositions, comprising a T lymphocyte, or a population thereof, expressing at least one recombinant polynucleotide encoding a cytokine that enhances T lymphocyte survival during the contraction phase of an immune response. The invention further provides an isolated T lymphocyte, or population thereof, expressing at least one recombinant polynucleotide encoding the cytokine, wherein the polynucleotide comprises a non-native coding sequence encoding the cytokine. Also provided is the use of such compositions and T lymphocytes, or populations thereof, for the treatment or prevention of a medical condition e.g., cancer. A method of preparing the a T lymphocyte with enhanced T cell survival is further provided herein.

REFERENCES:
patent: 4965195 (1990-10-01), Namen et al.
patent: 6809191 (2004-10-01), Qiu et al.
patent: 2003/0026790 (2003-02-01), Hwu et al.
patent: WO 95/27722 (1995-10-01), None
patent: WO 98/36768 (1998-08-01), None
patent: WO 98/36768 (1998-08-01), None
patent: WO 2004/034789 (2004-04-01), None
patent: WO 2004/059556 (2004-07-01), None
patent: WO 2004/059556 (2004-07-01), None
Kim et al. Human Gene Therapy 5:1457-1466; 1994.
Klebanoff et al. (Feb. 17, 2004) PNAS, vol. 101(7) 1969-1974.
Ishimitsu et al. (2001) J. Immunol., vol. 166(3), 1991-2001.
Marks-Konczalik et al. (2000) PNAS, vol. 97 (21) 11445-11450.
Bonini et al. (1997) Science, vol. 276, 1719-1724.
Liu et al. (2001)J. Immunol., vol. 67, 6356-6365.
Arthur et al.,Cancer Gene Ther., 4(1),17-25 (1997).
Bradel-Tretheway et al.,J Virol Meth., 111, 145-156 (2003).
Ishimitsu et al.,J. Immunol., 166(3), 1991-2001 (2001).
Klebanoff et al.,Proc. Natl. Acad. Sci. U.S.A., 101(7),1969-1974 (2004).
Marrack et al.,Ann. Rev. Immunol., 22, 765-787 (2004).
Oh et al.,Proc. Natl. Acad. Sci. U.S.A., 100(6), 3392-3397 (2003).
Perera et al.,Proc. Natl. Acad. Sci. U.S.A., 98(9),5146-5151 (2001)—online publication on Apr. 10, 2001.
Ramakrishna et al.,J. Virol., 78, 9174-9189 (2004).
Schluns et al.,Nature Rev. Immunol., 3, 269-279 (2003).
Verhoeyen et al.,Blood, 101(6), 2167-2174 (2003).
Xin et al.,Vaccine, 17(7-8),858-866 (1999).
Young et al.,Mol. Cell. Biol., 11(2), 854-863 (1991).
Hsu et al.,Journal of Immunology, 175(11):7226-7234 (Dec. 1, 2005).
Kim et al.,Human Gene Therapy, 5(12):1457-1466 (Dec. 1994).
Liu et al.,Journal of Immunology, 167(11):6356-6365 (Dec. 1, 2001).
Hofacker,Nucleic Acids Research, 31(13), 3429-3431 (2003).

Affiliated with

Also associated with

Rating

Adoptive immunotherapy with enhanced T lymphocyte survival does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Adoptive immunotherapy with enhanced T lymphocyte survival, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adoptive immunotherapy with enhanced T lymphocyte survival will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2715239